Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment
Open Access
- 23 December 2025
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 116 (4) , 416-424
Abstract
Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors and new combinations of chemotherapy and targeted drugs. It is unclear what effect these changes have had on overall survival in the real‐world clinical setting over time. We retrospectively analyzed 501 patients with ND AML treated at an urban academic cancer center from 2015 to 2022 with respect to survival rates and treatment regimen utilization trends over time, in the context of AML risk category and whether allogeneic stem cell transplantation (HSCT) occurred. Among European LeukemiaNet 2022 intermediate risk ND AML patients who did not undergo HSCT, overall survival and relapse‐free survival improved significantly in the early versus later cohort (2015–2018 vs. 2019–2022, respectively). These gains were not observed in the adverse‐risk subgroup, where outcomes remain unchanged. First‐line use of hypomethylating agent‐based therapies increased seven‐fold, while reliance on chemotherapy alone decreased by half. These findings highlight a meaningful shift in treatment patterns associated with improved outcomes overall, but an ongoing lack of progress in the highest‐risk subgroups.Keywords
Funding Information
- Virginia Commonwealth University (UL1TR002649)
- National Cancer Institute (P30 CA016059)
This publication has 38 references indexed in Scilit:
- Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in SpainAnnals of Hematology, 2025
- AML treatment: conventional chemotherapy and emerging novel agentsTrends in Pharmacological Sciences, 2024
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectivesBlood Reviews, 2022
- Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialThe Lancet Oncology, 2021
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialThe Lancet Haematology, 2021
- Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNetTransplantation and Cellular Therapy, 2021
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2018
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous LeukemiaTransplantation and Cellular Therapy, 2016
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987